Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics, Millennium sign lymphoma deal

Executive Summary

Four days after losing a major partner for one of its lymphoma projects, Seattle Genetics penned another deal in the space, this time joining forces with Millennium: The Takeda Oncology Co. and its parent Takeda Pharmaceutical to develop SG's brentuximab vedotin (SGN35), in Phase II for relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Takeda comes out of the deal with exclusive rights to sell the compound worldwide, excluding the US and Canada.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register